SavedAdd your journal

Journals / Glokom Katarakt / 2011 / Cilt: 6 - Sayı: 1

Effect of central corneal thickness on the efficacy of topical latanoprost therapy in cases with primary open angle glaucoma

Primer açık açılı glokomlu olgularda topikal latanoprost tedavisinin etkinliği üzerine merkezi kornea kalınlığının etkisi

Kemal TÜRKYILMAZ
Adem TÜRK
Ali KURT
Pages
32–35
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, CCT measurements may be useful in interpreting clinical efficacy of latanoprost.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the effect of central corneal thickness (CCT) on the efficacy of topical latanoprost therapy in cases with primary open angle glaucoma (POAG).
📊
Key Findings & Data:Materials and Methods: In this prospective study, clinical findings of 54 eyes of 33 POAG patients were investigated.
💡
Conclusion & Impact:Therefore, CCT measurements may be useful in interpreting clinical efficacy of latanoprost.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the effect of central corneal thickness (CCT) on the efficacy of topical latanoprost therapy in cases with primary open angle glaucoma (POAG). Materials and Methods: In this prospective study, clinical findings of 54 eyes of 33 POAG patients were investigated. In all eyes, CCT was measured by ultrasonic pachymetry and intraocular pressure (IOP) by noncontact-tonometry and then the eyes were divided into thin (&#8804;540 micron) and thick (>540 micron) cornea groups. All eyes were treated with latanoprost 0.005% and the final IOP levels were measured at fourth week. CCT and IOP measurements in two groups were compared statistically and correlations between CCT and IOP decrease obtained with treatment were investigated. Results: In thin cornea group (n=28), mean CCTs were 525.07±18.06 micron and baseline IOP levels were 25.25±2.19 mmHg. These levels were 569.62±22.14 micron and 26.31±2.74 mmHg respectively in thick cornea group (n=26). The two groups did not differ in terms of baseline IOPs (p=0.122) but in CCTs (p<0.0001). In terms of mean IOP measurements at fourth week, the two groups were statistically different from each other (18.07±2.75 mmHg, and 22.15±3.77 mmHg respectively, p<0.0001). There was a significant correlation between CCT measurements and levels of IOP decrease obtained with treatment (r=-0.667, p<0.0001). Conclusion: IOP lowering effect of latanoprost is affected by CCT. Therefore, CCT measurements may be useful in interpreting clinical efficacy of latanoprost.

Özet

Amaç: Primer açık açılı glokomlu (PAAG) olgularda topikal latanoprost tedavisinin etkinliği üzerine merkezi kornea kalınlığının (MKK) etkisini değerlendirmek. Gereç ve Yöntem: Bu ileriye dönük çalışmada 33 PAAG’li hastaya ait 54 gözdeki klinik bulgular araştırıldı. Tüm gözlerde ultrasonik pakimetriyle MKK ve nonkontakt tonometriyle göz içi basıncı (GİB) ölçüldü. Daha sonra gözler ince (≤540 mikron) ve kalın (>540 mikron) kornealı gruplar olarak ayrıldı. Tüm gözler %0.005 latanoprost ile tedavi edildi ve dördüncü haftada sonuç GİB değerleri ölçüldü. İki gruptaki MKK ve GİB ölçümleri istatistiksel olarak karşılaştırıldı ve MKK ile tedaviyle elde edilen GİB düşüşü arasındaki ilişkiler incelendi. Bulgular: İnce kornealı grupta (n=28) ortalama MKK 525.07±18.06 mikron ve bazal GİB düzeyleri 25.25±2.19 mmHg idi. Bu değerler kalın kornealı grupta (n=26) sırasıyla 569.62±22.14 mikron ve 26.31±2.74 mmHg idi. İki grup arasında bazal GİB değerleri açısından farklılık yokken (p=0.122), MKK değerleri açısından farklılık mevcuttu (p<0.0001). Dördüncü haftada ölçülen ortalama GİB değerleri açısından iki grup arasında istatistiksel olarak anlamlı farklılık mevcuttu (sırasıyla 18.07±2.75 mmHg ve 22.15±3.77 mmHg, p<0.0001). MKK değerleri ve tedavi ile elde edilen GİB düşüş değerleri arasında istatistiksel olarak anlamlı bir korelasyon mevcuttu (r=-0.667, p<0.0001). Sonuç: Latanoprostun GİB düşürücü etkisi MKK’dan etkilenmektedir. Bu yüzden latanoprostun klinik etkinliğinin yorumlanmasında MKK ölçümleri faydalı olabilir.

🔖

Cite This Article

TÜRKYILMAZ, K., TÜRK, A., KURT, A. (2011). Effect of central corneal thickness on the efficacy of topical latanoprost therapy in cases with primary open angle glaucoma. Glokom Katarakt, Cilt: 6 - Sayı: 1, 32–35. https://ajindex.com/articles/226830

References (16)

  1. Akyol N, Türk A, Çabuk Y, ve ark.: Glokomda %0.005 latanoprost ve %2 carteolol tedavisinin etkinliğinin karşılaştırılması. Glo-Kat. 2006;1:119-122
  2. Thomas R, Parikh R, Muliyil J, et al.: Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes. Indian J Ophthalmol. 2003;51:123-128
  3. Çolak N, Horozoglu F.: Primer açık açılı glokomlu ve oküler hipertansiyonlu hastalarda latanoprost, bimatoprost ve travoprost’un etkilerinin karşılaştırılması. T. Oft. Gaz. 2008;38:473-480
  4. Thomas R, Parikh R, Sood D, et al.: Efficacy and safety of latanoprost for glaucoma treatment: a three-month multicentric study in India. Indian J Ophthalmol. 2005;53:23-30
  5. Strutton DR, Walt JG.: Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma. 2004;13:221-226
  6. Lee DA, Higginbotham EJ.: Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005;62:691-699
  7. Watson PG.: Latanoprost. Two years’ experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105:82-87
  8. Oh JY, Park KH.: The effect of latanoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Korean J Ophthalmol. 2005;19:297-301
  9. Ravinet E, Mermoud A, Brignoli R.: Four years later: a clinical update on latanoprost. Eur J Ophthalmol. 2003;13:162-175
  10. Ozdemir M, Ozdemir G.: Comparison of the intraocular pressure lowering effect of latanoprost and carteolol-pilocarpine combination in newly diagnosed glaucoma. Jpn J Ophthalmol. 2003;47:72-76
  11. Reardon G, Schwartz GF, Mozaffari E.: Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol. 2003;13:44-52
  12. Kjellgren D, Douglas G, Mikelberg FS, et al.: The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmol Scand. 1995;73:233-236
  13. Camras CB, Schumer RA, Marsk A, et al.: Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol. 1992;110:1733-1738
  14. Yaşar T, Kurt A, Karadağ F, ve ark.: Latanoprost monoterapisinin uzun dönem sonuçları. Glo-Kat. 2007;2:271-273
  15. Rossetti L, Gandolfi S, Traverso C, et al.: An evaluation of the rate of nonresponders to latanoprost therapy. J Glaucoma. 2006;15:238-243
  16. Hedman K, Larsson LI.: The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle